Adjunctive, Low-dose tPA in Primary PCI for STEMI

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 210 participants.

Also called NCT03335839

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 210 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03335839
Other papers using this trial's data
  • Intracoronary Low-Dose Recombinant Tissue Plasminogen Activator in Primary PCI for ST-Segment Elevation Myocardial Infarction and Large Thrombus Burden: A Randomized Trial Journal of the American College of Cardiology, 2026-01-27 DOI, PubMed 41194755

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03335839. Randomized; triple masking; primary purpose treatment. Start 2018-04-01 (actual); primary completion 2024-09-17 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Adjunctive, Low-dose tPA in Primary PCI for STEMI
Acronym
STRIVE
Intervention (Drug)
tissue plasminogen activator
Intervention (Other)
Saline
Lead sponsor
Population Health Research Institute (class: other)
Collaborator
Heart and Stroke Foundation of Canada (class: other)

Record details

Record id
cardio:ct-nct03335839
Content hash
9499a509ecd294f0e21184a5f2eb737bf1d3df9213ef94417a438ee7d7750b04